OBJECTIVES: The re-evaluation of products by the HAS may result in changes to their Assessment of the Medical Benefit (ASMR). However, the impact of these ASMR changes on the list price of products remains inadequately documented.

METHODS: All re-evaluation of the Assessment of the Medical Benefit (ASMR) by the HAS spanning from January 2017 to March 2023 were extracted from explore.data.gouv. To identify the relevant cases for analysis, all products exhibiting distinct ASMR values between their previous evaluation (inscription or previous re-evaluation) and the subsequent re-evaluation were isolated. For all products with an ASMR change, their list price was analyzed using the NAVLIN database to identify any potential increase or decrease following the 12-month period after the publication of the re-evaluation by the HAS

RESULTS: Out of the 212 ASMR re-evaluations conducted between January 2017 and March 2023, 33 products experienced a change in their ASMR rating. Among the 33 products, 19 witnessed an increase in their ASMR, while 14 saw a decrease. Only 4 products had a change in their list price. The table below presents the products, their corresponding ASMR changes, and the associated price changes:

• LEVACT (bendamustine) - AMSR changed from III to V - List Price: -40%
• MYOZYME (alpha alglucosidase) - ASMR changed from II to III - List Price: -9%
• TYSABRI (natalizumab) - ASMR changed from III to IV - List Price: -10%
• VOTRIENT (pazopanib) - ASMR changed from IV to V - List Price: -10%

CONCLUSIONS: The findings of this research suggest that while some products experience a change in ASMR after a re-evaluation by the HAS, only a small proportion of products show an adjustment in list price, and this adjustment is always a decrease in price.